(UroToday.com) In the on-demand poster session of the European Society for Medical Oncology (ESMO) Annual Congress, Dr. Jonathan Rosenberg presented a subgroup analysis of the EV-301 trial. This phase III trial (NCT03474107) demonstrated that treatment with enfortumab vedotin (EV) showed superior overall survival (OS) compared with standard chemotherapy (SC) in patients with previously treated locally advanced or metastatic urothelial carcinoma (la/mUC). This subgroup analysis reports on the efficacy and safety of EV for those with poor prognostic factors.